The short answer
Osphena (ospemifene) is an FDA-approved daily pill for moderate-to-severe painful intercourse (dyspareunia) and moderate-to-severe vaginal dryness caused by menopause. It is a selective estrogen receptor modulator (SERM): not a hormone, but it acts like estrogen on vaginal tissue. It carries a boxed warning about endometrial cancer and stroke or blood-clot risk.
Boxed warning: endometrial cancer and cardiovascular disorders
Ospemifene acts like estrogen on the uterine lining. In a person with a uterus, estrogen-like stimulation without a progestin can increase the risk of endometrial hyperplasia and cancer. Any unexpected vaginal bleeding needs prompt evaluation.
The label also warns of stroke and deep vein thrombosis. The current label (DailyMed, February 2025) lists these contraindications: undiagnosed abnormal genital bleeding, estrogen-dependent cancer, current or past blood clots, current or past stroke or heart attack, serious allergy to ospemifene, and pregnancy or possible pregnancy. The FDA's 2025 hormone therapy boxed-warning initiative does not apply to Osphena, which is not an estrogen product; its own boxed warning is unchanged. It should be used for the shortest duration consistent with treatment goals and risks.
Current label check
The medication-specific claims on this page were checked against these current product labels on 2026-10-03.
| Product label | Label date | Boxed warning on that label |
|---|---|---|
| Osphena (ospemifene) tablets | 2025-02-14 | Endometrial cancer and cardiovascular disorders |
Established evidence
What Osphena is approved to treat
Osphena is approved for moderate-to-severe dyspareunia (painful sex) and moderate-to-severe vaginal dryness that are symptoms of vulvar and vaginal atrophy due to menopause. These are part of the broader genitourinary syndrome of menopause (GSM), which can also include urinary urgency, burning, and recurrent infections.
It is not approved for hot flashes and may cause them. It is not approved for osteoporosis, though another SERM, raloxifene, is.
Established evidence
How a SERM works on vaginal tissue
SERMs bind estrogen receptors but act differently in different tissues. Ospemifene has estrogen-like activity in the vaginal lining, which helps rebuild superficial cells, lower vaginal pH, and improve moisture and elasticity. Its effects in breast tissue have not been fully established in long-term outcome studies, which is why the label is cautious about breast cancer history.
Established evidence
What the trials showed
Twelve-week randomized, placebo-controlled trials in postmenopausal women found improvements in vaginal cell maturation, vaginal pH, and the severity of the most bothersome symptom, painful intercourse or dryness, compared with placebo. Longer safety studies looked at the uterine lining for up to a year.
Established evidence
How it is taken
Osphena is a tablet taken by mouth once daily with food. Because it is systemic rather than local, it reaches the whole body, which is the main trade-off against low-dose vaginal therapies.
Established evidence
Common side effects
- Hot flashes
- Vaginal discharge
- Muscle spasms
- Increased sweating
- Genital discharge or bleeding, which always warrants evaluation
Established evidence
Interactions and contraindications
- Do not use with estrogens or other SERMs
- Fluconazole and other strong CYP inhibitors can raise ospemifene levels; the label advises against use with fluconazole
- Rifampin and other inducers can lower levels
- Contraindicated with current or past blood clots, current or past stroke or heart attack, estrogen-dependent cancer, undiagnosed genital bleeding, hypersensitivity, or pregnancy
- Not studied in severe liver impairment
Osphena vs vaginal estrogen vs prasterone
All three treat menopause-related painful sex, but they differ in route and safety profile. Guidelines generally consider low-dose vaginal estrogen first-line for GSM in most people.
| Feature | Osphena (ospemifene) | Vaginal estrogen | Intrarosa (prasterone) |
|---|---|---|---|
| Form | Daily oral tablet | Cream, tablet, insert, or ring | Nightly vaginal insert |
| What it is | SERM, not a hormone | Estradiol or conjugated estrogens | DHEA, a hormone precursor |
| Boxed warning (labels checked Oct 2026) | Yes: endometrial cancer and cardiovascular disorders | Varies by product: Estring has none; Vagifem, Imvexxy, Estrace cream and Premarin cream still carry the older boxed warning | None |
| Treats urinary GSM symptoms | Not an approved use | Commonly used; evidence supports benefit | Not an approved use |
| Good for people who cannot use vaginal products | Yes, it is a pill | No | No |
Questions to ask a healthcare professional
- Is vaginal estrogen, ospemifene, or prasterone the better fit for my history?
- Do I need endometrial monitoring if I still have a uterus?
- Does my clotting or stroke history rule this out?
- How long would I take it, and when would we reassess?
Questions, answered
What people ask about Osphena
Is Osphena a hormone?+
No. Ospemifene is a selective estrogen receptor modulator. It acts like estrogen in vaginal tissue but is not estrogen.
Is Osphena FDA approved?+
Yes, for moderate-to-severe dyspareunia and moderate-to-severe vaginal dryness due to menopause.
Does Osphena cause hot flashes?+
It can. Hot flashes are one of the most common side effects listed on the label.
Can I take Osphena with vaginal estrogen?+
The label advises against using ospemifene with estrogens or other SERMs.
Does Kindr Health offer Osphena?+
This page is educational and does not state or imply availability through Kindr Health.
Kindr Health does not claim to offer Osphena on this page. Availability and prescribing are not implied.
A broader care pathway
Explore menopause care
Learn how Kindr Health care pathways work. An educational page is not a statement that this medication is available or appropriate for you.
SOURCES & REFERENCES
Every clinical claim on this page is sourced.
- Osphena prescribing information (current label) (2026) — DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Osphena
- The 2020 genitourinary syndrome of menopause position statement (2020) — The Menopause Society (Menopause journal). pubmed.ncbi.nlm.nih.gov/32852449
- Vaginal dryness and genitourinary syndrome of menopause (2023) — ACOG. www.acog.org/womens-health/faqs/when-sex-is-painful
This resource is educational and does not replace individualized medical advice. Do not start, stop, or change a prescription without guidance from a licensed healthcare professional.